HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

IL-17 receptor goes solo in autoimmune inflammation.

Abstract
IL-17-blocking antibodies have shown little clinical effect in some autoimmune diseases such as multiple sclerosis. In this issue of Immunity, Luo et al. demonstrate that SHP2-Act1 complexes can mediate autonomous IL-17R signaling in the absence of the IL-17 ligand itself.
AuthorsStefan Bittner, Frauke Zipp
JournalImmunity (Immunity) Vol. 56 Issue 9 Pg. 1977-1980 (09 12 2023) ISSN: 1097-4180 [Electronic] United States
PMID37703825 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Comment)
CopyrightCopyright © 2023 Elsevier Inc. All rights reserved.
Chemical References
  • Interleukin-17
  • Receptors, Interleukin-17
  • Antibodies, Blocking
Topics
  • Humans
  • Interleukin-17
  • Receptors, Interleukin-17
  • Antibodies, Blocking
  • Autoimmune Diseases
  • Inflammation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: